Printer Friendly

ARGUS PHARMACEUTICALS TO START HUMAN CLINICAL TRIALS ON POTENTIAL LEUKEMIA TREATMENT

 HOUSTON, Jan. 14 /PRNewswire/ -- Argus Pharmaceuticals, Inc. has received clearance from the Food and Drug Administration to begin human clinical trials on its anticancer compound, AR-623 (Tretinoin(LS)(TM), I.V.), for the treatment of leukemia.
 The initial Phase I study, designed to determine safety and pharmacology, will be conducted at The University of Texas M.D. Anderson Cancer Center in Houston, Texas.
 AR-623 is a unique formulation of all trans retinoic acid, or tretinoin. The product is designed to deliver the drug to sites where leukemic cells are formed and, once there, to induce them via a novel mechanism of action to develop as normal cells.
 According to figures from the American Cancer Society, leukemia was expected to afflict approximately 28,000 new patients in the United States during 1992.
 Argus Pharmaceuticals is a publicly traded company (NASD: ARGS) which develops proprietary pharmaceuticals for the treatment of cancer and infectious diseases. Argus holds the exclusive rights to more than a decade of research on macrophages and lipid carriers conducted by a team of scientists at The University of Texas M.D. Anderson Cancer Center.
 -0- 1/14/93
 /CONTACT: Kenneth M. Cohen, vice president - business affairs of Argus Pharmaceuticals, Inc., 713-367-1666, or Bryan Oakley of Edelman Public Relations, 713-623-2666, for Argus Pharmaceuticals/
 (ARGS)


CO: Argus Pharmaceuticals, Inc. ST: Texas IN: MTC SU:

SH -- NY032 -- 4843 01/14/93 11:38 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1993
Words:232
Previous Article:DECEMBER TRAFFIC RELEASED FOR MESA AIRLINES
Next Article:FOREST SERVICE SPOTTED OWL GUIDELINES HINDER STATE ECONOMIC RECOVERY EFFORTS
Topics:


Related Articles
PROTEIN DESIGN LABS ANNOUNCES START OF HUMAN CLINICAL TRIALS FOR SMART M195 ANTIBODY TO TREAT MYELOID LEUKEMIA
ARGUS PHARMACEUTICALS BEGINS HUMAN CLINICAL TRIALS ON POTENTIAL LEUKEMIA TREATMENT
ARGUS PHARMACEUTICALS, INC. REPORTS SECOND QUARTER 1994 RESULTS
M.D. ANDERSON RESEARCHERS DEMONSTRATE ABILITY TO OVERCOME MAJOR OBSTACLE TO PROMISING LEUKEMIA TREATMENT
ARGUS PHARMACEUTICALS, INC. REPORTS THIRD QUARTER 1994 RESULTS
ARGUS PHARMACEUTICALS, INC., TRIPLEX PHARMACEUTICAL CORPORATION AND ONCOLOGIX, INC. AGREE TO MERGE
ARONEX (FORMERLY ARGUS PHARMACEUTICALS) INITIATES PHASE II CLINICAL EFFICACY STUDY OF TRETINOINLF FOR LEUKEMIA
Cell Genesys Reports Encouraging Preclinical Data for GVAX(R) Vaccine in Acute Leukemia.
Cell Genesys Initiating Phase II Trial Of GVAX(R) Cancer Vaccine for Acute Leukemia.
Cell Genesys Reports Encouraging Interim Results From Phase I Trial of GVAX(R) Cancer Vaccine for Acute Leukemia.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters